Doris M. Murray

1.5k total citations · 1 hit paper
5 papers, 791 citations indexed

About

Doris M. Murray is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Organic Chemistry. According to data from OpenAlex, Doris M. Murray has authored 5 papers receiving a total of 791 indexed citations (citations by other indexed papers that have themselves been cited), including 4 papers in Oncology, 2 papers in Pulmonary and Respiratory Medicine and 1 paper in Organic Chemistry. Recurrent topics in Doris M. Murray's work include HER2/EGFR in Cancer Research (3 papers), Cancer Treatment and Pharmacology (2 papers) and Lung Cancer Treatments and Mutations (2 papers). Doris M. Murray is often cited by papers focused on HER2/EGFR in Cancer Research (3 papers), Cancer Treatment and Pharmacology (2 papers) and Lung Cancer Treatments and Mutations (2 papers). Doris M. Murray collaborates with scholars based in United States and United Kingdom. Doris M. Murray's co-authors include Barry R. Keith, Robert J. Mullin, David W. Rusnak, Tona M. Gilmer, Karen Affleck, Karen Lackey, Edgar R. Wood, Wilson B. Knight, Nelson Rhodes and Krystal J. Alligood and has published in prestigious journals such as Bioorganic & Medicinal Chemistry Letters, Cancer Immunology Immunotherapy and PubMed.

In The Last Decade

Doris M. Murray

5 papers receiving 766 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo.

2001 590 citations David W. Rusnak, Karen Lackey et al. PubMed profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Doris M. Murray United States	4	525	331	207	167	134	5	791
Andrew Dorr United States	16	356 0.7×	737 2.2×	147 0.7×	44 0.3×	95 0.7×	37	1.0k
Karin Amundson United States	6	332 0.6×	429 1.3×	260 1.3×	34 0.2×	147 1.1×	14	781
Nicole Giocanti France	12	488 0.9×	499 1.5×	287 1.4×	125 0.7×	35 0.3×	28	933
Lawrence Panasci Canada	14	416 0.8×	311 0.9×	95 0.5×	70 0.4×	75 0.6×	32	656
Carolyn Paradise United States	6	1.3k 2.4×	608 1.8×	96 0.5×	85 0.5×	92 0.7×	7	1.7k
Andrea Stern Ferris United States	3	580 1.1×	570 1.7×	58 0.3×	150 0.9×	110 0.8×	6	1.1k
David E. MacCallum United Kingdom	11	472 0.9×	739 2.2×	102 0.5×	38 0.2×	58 0.4×	21	1.1k
Guenther R. Adolf Austria	8	669 1.3×	474 1.4×	468 2.3×	83 0.5×	28 0.2×	15	1.0k
Heiko Maacke Switzerland	14	493 0.9×	656 2.0×	152 0.7×	46 0.3×	59 0.4×	21	902
Berend Neuteboom United States	13	476 0.9×	251 0.8×	107 0.5×	202 1.2×	23 0.2×	19	877

Countries citing papers authored by Doris M. Murray

Since Specialization

Citations

This map shows the geographic impact of Doris M. Murray's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Doris M. Murray with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Doris M. Murray more than expected).

Fields of papers citing papers by Doris M. Murray

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Doris M. Murray. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Doris M. Murray. The network helps show where Doris M. Murray may publish in the future.

Co-authorship network of co-authors of Doris M. Murray

This figure shows the co-authorship network connecting the top 25 collaborators of Doris M. Murray. A scholar is included among the top collaborators of Doris M. Murray based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Doris M. Murray. Doris M. Murray is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

5 of 5 papers shown

1.

Mullin, Robert J., Doris M. Murray, James A. Onori, & Barry R. Keith. (2004). Xenograft response to combination therapy with the ErbB1-ErbB2 tyrosine kinase inhibitor GW572016.. 64. 882–882. 3 indexed citations

2.

Gaul, Micheal D., Yu Guo, Karen Affleck, et al.. (2003). Discovery and Biological Evaluation of Potent Dual ErbB-2/EGFR Tyrosine Kinase Inhibitors: 6-Thiazolylquinazolines. Bioorganic & Medicinal Chemistry Letters. 13(4). 637–640. 40 indexed citations

3.

Thurmond, Linda M., et al.. (2003). Adenocarcinoma cells exposed in vitro to Navelbine or Taxol increase Ep-CAM expression through a novel mechanism. Cancer Immunology Immunotherapy. 52(7). 429–437. 8 indexed citations

4.

Rusnak, David W., Karen Lackey, Karen Affleck, et al.. (2001). The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo.. PubMed. 1(2). 85–94. 590 indexed citations breakdown →

5.

Austin, Elizabeth A., et al.. (1995). Enzyme/prodrug gene therapy: comparison of cytosine deaminase/5-fluorocytosine versus thymidine kinase/ganciclovir enzyme/prodrug systems in a human colorectal carcinoma cell line.. PubMed. 55(21). 4808–12. 150 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact